ArticleRadiology2021
Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.
Open access · greenAbstract read
In one paragraph
Article in Radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Activatable MRI nanoprobes for tumor and immune microenvironment imaging: biological mechanisms and translational implications.Materials today. Bio · 2026Review
- Theranostic Potentials of Metallic Nanoparticles in Thyroid Diseases: Challenges and Prospects.International journal of nanomedicine · 2026Review
- Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & diseases · 2025Review
- Localized In Vivo Prodrug Activation Using Radionuclides.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- New Horizons of Biomarkers in Metastatic Thyroid Cancer.Journal of Cancer · 2025Review
- Ultrasound-guided radiofrequency ablation for the treatment of anaplastic thyroid cancer: a case report.Frontiers in oncology · 2025Article
- Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine.Discover oncology · 2024Review
- Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time.Frontiers in immunology · 2023Review
- Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release.Bioconjugate chemistry · 2022Article
- Probing immune infiltration dynamics in cancer by in vivo imaging.Current opinion in chemical biology · 2022Review
- A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.Frontiers in immunology · 2022Article
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Nanoparticles to Target and Treat Macrophages: The Ockham's Concept?Pharmaceutics · 2021Review
- Programmed cell death, redox imbalance, and cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2021Review
- Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.Nature nanotechnology · 2021Article
- Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Thomas S C NgFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0002-3676-1800
Viswanath GundaFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).
Ran LiFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0002-8537-8824
Mark PrytyskachFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).
Yoshiko IwamotoFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0002-3723-1043
Rainer H KohlerFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0001-6269-6590
Sareh ParangiFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).
Ralph WeisslederFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0003-0828-4143
Miles A MillerFrom the Center for Systems Biology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Suite 5.210, Boston, MA 02114 (T.S.C.N., R.L., M.P., Y.I., R.H.K., R.W., M.A.M.); Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (T.S.C.N.); Departments of Surgery (V.G., S.P.) and Radiology (R.L., R.W., M.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; and Department of Systems Biology, Harvard Medical School, Boston, Mass (R.W.).ORCID 0000-0001-7638-8898
Brigham and Women's Hospital · US
Funding
Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1MFAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3MImaging of nanotherapeutic drug actionU01CA206997 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$2.9MImaging tumor associated macrophage (TAM) functionR01CA206890 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PITTET, MIKAEL, WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$1.9MSingle Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast CancerR00CA207744 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, MILES A · 2018 to 2020
$747kNCI NIH HHS R00 CA207744NCI NIH HHS R01 CA206890NCI NIH HHS R01 CA257623NCI NIH HHS T32 CA079443NCI NIH HHS U01 CA206997
Abstract
Background Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the immunosuppressive microenvironment created by tumor-associated macrophages (TAMs). Purpose To understand the relationship between TAM infiltration, tumor vascularization, and corresponding drug delivery by using ferumoxytol-enhanced MRI and macrin in an ATC mouse model. Materials and Methods ATC tumors were generated in 6-8-week-old female B6129SF1/J mice through intrathyroid injection to model orthotopic tumors, or intravenously to model hematogenous metastasis, and prospectively enrolled randomly into treatment cohorts (
Indexed as
AnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenCell Line, TumorDisease Models, AnimalFemaleFerrosoferric OxideImmunityMagnetic Resonance ImagingMiceNanoparticlesProto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticTumor-Associated MacrophagesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabB7-H1 AntigenFerrosoferric OxideProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.